Refine
Year of publication
Document Type
- Preprint (668)
- Article (468)
- Book (2)
- Conference Proceeding (1)
- Working Paper (1)
Has Fulltext
- yes (1140)
Is part of the Bibliography
- no (1140)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (8)
- Heavy-ion collision (6)
- ALICE experiment (4)
- COVID-19 (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- prostate cancer (4)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- radical prostatectomy (3)
- ACLF (2)
- ALICE (2)
- Beauty production (2)
- Biodiversity (2)
- Charm physics (2)
- Corona (2)
- EGFR (2)
- Epileptischer Anfall (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Fasting (2)
- Glioblastoma (2)
- Glucose (2)
- Heavy Quark Production (2)
- Immunology (2)
- Ketogenic diet (2)
- Leptin (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Liver diseases (2)
- Liver transplantation (2)
- Nephrons (2)
- Pandemic (2)
- Pandemie (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Pre-analytics (2)
- QCD (2)
- Radiation (2)
- SARS-CoV-2 (2)
- SARS-CoV‑2 (2)
- Seizure (2)
- Single electrons (2)
- Status epilepticus (2)
- acute myeloid leukemia (2)
- acute-on-chronic liver failure (2)
- gene therapy (2)
- portal hypertension (2)
- transient elastography (2)
- 2-deoxyglucose (2-DG) (1)
- ALICE detector (1)
- APRI (1)
- ASAP (1)
- ATP (1)
- Advanced stage (1)
- Allergic asthma (1)
- Alpha-synuclein (1)
- Amino acid analysis (1)
- Anti-kaon–nucleon physics (1)
- Anti-nuclei (1)
- Awareness campaign (1)
- BCOR (1)
- BCORL1 (1)
- Blood (1)
- Blood sample handling (1)
- Bodensee (1)
- Bodensee-Gebiet (1)
- Boosted Jets (1)
- Brain tumor (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COVID‐19 (1)
- Caco-2 cells (1)
- Cancer (1)
- Cancer check up (1)
- Cancer models (1)
- Cancer treatment (1)
- Cell motility (1)
- Central Bank Communication (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cirrhosis (1)
- Clinical Trials and Observations (1)
- Clinical presentation (1)
- Collective Flow, (1)
- Colorectal cancer (1)
- Comparative analysis (1)
- Comparison with QCD (1)
- Complex II (1)
- Complicated stage (1)
- Computed axial tomography (1)
- Computer-aided drug design (1)
- Congenital anomalies (1)
- Congenital ocular motor apraxia (1)
- Conservation biology (1)
- Cytoskeletal proteins (1)
- DNA sequence analysis (1)
- DTHR (1)
- Data management (1)
- Death rates (1)
- Deep neural network (1)
- Developmental biology (1)
- Devic disease (1)
- Devic syndrome (1)
- Diabetes (1)
- Diabetes mellitus (1)
- D’Amico classification (1)
- EBV (1)
- EWSR1 (1)
- Ecosystems (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Embryos (1)
- Endocannabinoids (1)
- Environment (1)
- Environmental impact (1)
- Everolimus (1)
- Evidence-based guidelines (1)
- FIB-4 (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- First-line regimen (1)
- Flohkrebse (1)
- Forschung (1)
- GABARAP (1)
- Gene expression (1)
- Gene fusion (1)
- Genetic engineering (1)
- Gleason Score (1)
- Gleason score (1)
- Gradient boosting (1)
- HBT (1)
- HBV (1)
- HIV (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hepatitis C virus (1)
- Hepatocellular carcinoma (1)
- Hif-1 alpha (1)
- Hispanic people (1)
- HoLEP (1)
- Holmium laser enucleation (1)
- Hyperammonemic encephalopathy (1)
- Hyperons (1)
- Hypertension (1)
- IHC (1)
- Imidacloprid (1)
- Immune suppression (1)
- Immunohistochemistry techniques (1)
- Incidental prostate cancer (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Invertebrates (1)
- Ionisation energy loss (1)
- Isothermal Titration Calorimetry (1)
- Jet Physics (1)
- Jet Substructure (1)
- Joubert syndrome (1)
- K3EDTA plasma sampling (1)
- Kaonic nuclei (1)
- Kd determination (1)
- Kidney transplantation (1)
- Konstanz (1)
- LABAs (1)
- LC3 (1)
- LEOSS (1)
- LIR motifs (1)
- LTER (1)
- Landkreis Konstanz (1)
- Lehre (1)
- Leukaemia (1)
- Lipidomics (1)
- Long‐term ecosystem research (1)
- Low energy QCD (1)
- MN1 (1)
- MR-spectroscopy (1)
- Machine learning (1)
- Material budget (1)
- Metabolomics (1)
- Metastasis (1)
- Metastatic tumors (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Molar tooth sign (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-syndrome classification (1)
- Multi-wire proportional drift chamber (1)
- Multiple stressors (1)
- Muscheln (1)
- Mutation databases (1)
- Myeloid Neoplasia (1)
- NETs (1)
- NMO-IgG (1)
- NMR spectroscopy (1)
- Nanoplastics (1)
- Natural Language Processing (1)
- Neonatal urea cycle disorders (1)
- Neural Network (1)
- Neural network (1)
- Neurodegenerative syndromes (1)
- Neuroepithelial (1)
- Neuromyelitis optica (1)
- Neurooncology (1)
- Neutrophils (1)
- Nuclear modification factor (1)
- Nucleus (1)
- ORL (1)
- Observation (1)
- Oncology (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- PATZ1 (1)
- PSA (1)
- PSA screening (1)
- PSA-Screening (1)
- PTDM (1)
- PTEN (1)
- Paediatrics (1)
- Parkinson’s disease (1)
- Partial wave analysis (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Pediatric (1)
- Plasma (1)
- Post-transplant (1)
- Predictive model (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Prostate cancer (1)
- Proton (1)
- Proton–proton (1)
- Prävention (1)
- Psoriasis vulgaris (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- ROS/RNS (1)
- Radiation exposure (1)
- Radical nephrectomy (1)
- Random forest (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Renal cancer (1)
- Renal system (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SPSS (1)
- SW480 cells (1)
- Sampling protocol (1)
- See (1)
- Serum (1)
- Single muons (1)
- Site networks (1)
- Socio-ecology (1)
- Specialist training (1)
- Stem-cell therapies (1)
- Strangeness (1)
- Support vector machine (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival analysis (1)
- Systematic Uncertainty (1)
- TOR inhibitor (1)
- TR (1)
- TUR-P (1)
- Teaching (1)
- Thermal desorption GC–MS (1)
- Tierökologie (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transcriptome analysis (1)
- Transfer Learning (1)
- Transition radiation detector (1)
- Transurethral resection of the prostate (1)
- Treatment (1)
- Treatment modification (1)
- Trigger (1)
- University hospitals (1)
- Universitätskliniken (1)
- VEGFR (1)
- Vector Boson Production (1)
- Vorsorgeuntersuchung (1)
- Warburg effect (1)
- Weiterbildung (1)
- Word Embedding (1)
- Xenon-based gas mixture (1)
- accessory proteins (1)
- acoustic radiation force impulse (1)
- acoustic radiation force impulse imaging (1)
- acute chronic inflammation (1)
- acute decompensation (1)
- adipogenesis (1)
- adjuvant chemotherapy (1)
- advanced melanoma (1)
- amino acids (1)
- amphiregulin (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- aortic stenosis (1)
- aquaporin-4 (AQP4) antibody (1)
- arthritis (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- atypical EGFR mutations (1)
- autophagy (1)
- bronchial allergen challenge (1)
- cART (1)
- cardiac remodeling (1)
- cell-free protein synthesis (1)
- cerebrospinal fluid (1)
- chromosomal integration (1)
- chronic hepatitis C (1)
- cirrhosis (1)
- clinical features (1)
- clinically important restrictions and symptoms (1)
- complete response (1)
- computed tomography (1)
- concordance (1)
- correlation (1)
- cytarabine dose (1)
- dE/dx (1)
- data management (1)
- data quality (1)
- deferred treatment (1)
- delayed treatment (1)
- desensitization (1)
- detector (1)
- diet (1)
- diffusion-weighted magnetic resonance imaging (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease progression (1)
- downgrading (1)
- elderly (1)
- electroencephalography (EEG) (1)
- electronic diaries (1)
- endocrine-disrupting chemicals (1)
- epidemiology (1)
- epiregulin (1)
- experimental results (1)
- fasting (1)
- fibrotest (1)
- fusion biopsy (1)
- gastrointestinal stromal tumours (1)
- gene vectors (1)
- glioblastoma (1)
- glycolysis (1)
- haemophilia treatment (1)
- health-relatedquality of life (1)
- heart failure (1)
- heavy ion experiments (1)
- hematopoietic stem cells (1)
- hepatic encephalopathy (1)
- histological outcomes (1)
- immunohistochemistry (1)
- immunologic (1)
- inhaled steroids (1)
- interstitial lung disease (1)
- intrinsically disordered region (1)
- inverse stage migration (1)
- isocaloric ketogenic diet (1)
- ketogenic (1)
- ketone body (1)
- liver (1)
- liver cirrhosis (1)
- logistic models (1)
- long-acting β2-agonists (1)
- longitudinally extensive transverse myelitis (1)
- loss-of-function (1)
- machine learning (1)
- magnetic resonance imaging (1)
- mechanical ventilation (1)
- metabolic cancer therapy (1)
- metabolic disruptors (1)
- multicenter study (1)
- multiplexed immunofluorescence (1)
- myositis (1)
- neoadjuvant chemoradiotherapy (1)
- neurological manifestations (1)
- non-invasive fibrosis assessment (1)
- non-small-cell lung cancer (1)
- non-target chemical analysis (1)
- nonstructural proteins (1)
- nonviral gene delivery (1)
- obesogens (1)
- observational study (1)
- oral cavity cancer (1)
- point shear wave elastography (1)
- pollen allergy (1)
- portosystemic shunt (1)
- ppK − (1)
- predictive biomarker (1)
- predictive biomarkers (1)
- preschool asthma (1)
- prognosis (1)
- prostate neoplasm (1)
- prostate-specific antigen (1)
- pulmonary failure (1)
- quark gluon plasma (1)
- radical prostatecomy (1)
- rare disease (1)
- rats (1)
- recurrent optic neuritis (1)
- respiratory failure (1)
- risk factors (1)
- risk stratification (1)
- second-line immunotherapy (1)
- severe uncontrolled asthma (1)
- spectra (1)
- spontaneous portosystemic shunt (1)
- stage II/III colorectal cancer (1)
- structural proteins (1)
- survival (1)
- systematic biopsy (1)
- targeted therapy (1)
- tiotropium (1)
- tolerance (1)
- transposition (1)
- treatment centres (1)
- tumor weight (1)
- tyrosine kinase inhibitors (1)
- upgrading (1)
- waiting time (1)
- Öffentlichkeit (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1035)
- Frankfurt Institute for Advanced Studies (FIAS) (954)
- Informatik (920)
- Medizin (69)
- Geowissenschaften (11)
- Biowissenschaften (5)
- Institut für Ökologie, Evolution und Diversität (4)
- Biochemie, Chemie und Pharmazie (3)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
The emerging disciplines of lipidomics and metabolomics show great potential for the discovery of diagnostic biomarkers, but appropriate pre-analytical sample-handling procedures are critical because several analytes are prone to ex vivo distortions during sample collection. To test how the intermediate storage temperature and storage period of plasma samples from K3EDTA whole-blood collection tubes affect analyte concentrations, we assessed samples from non-fasting healthy volunteers (n = 9) for a broad spectrum of metabolites, including lipids and lipid mediators, using a well-established LC-MS-based platform. We used a fold change-based approach as a relative measure of analyte stability to evaluate 489 analytes, employing a combination of targeted LC-MS/MS and LC-HRMS screening. The concentrations of many analytes were found to be reliable, often justifying less strict sample handling; however, certain analytes were unstable, supporting the need for meticulous processing. We make four data-driven recommendations for sample-handling protocols with varying degrees of stringency, based on the maximum number of analytes and the feasibility of routine clinical implementation. These protocols also enable the simple evaluation of biomarker candidates based on their analyte-specific vulnerability to ex vivo distortions. In summary, pre-analytical sample handling has a major effect on the suitability of certain metabolites as biomarkers, including several lipids and lipid mediators. Our sample-handling recommendations will increase the reliability and quality of samples when such metabolites are necessary for routine clinical diagnosis.
Endocannabinoids (ECs) are potent lipid mediators with high physiological relevance. They are involved in a wide variety of diseases like depression or multiple sclerosis and are closely connected to metabolic parameters in humans. Therefore, their suitability as a biomarker in different (patho-)physiological conditions is discussed intensively and predominantly investigated by analyzing systemic concentrations in easily accessible matrices like blood. Carefully designed pre-analytical sample handling is of major importance for high-quality data, but harmonization is not achieved yet. Whole blood is either processed to serum or plasma before the onset of analytical workflows and while knowledge about pre-analytical challenges in plasma handling is thorough they were not systematically investigated for serum.
Therefore, the ECs AEA and 2-AG, and closely related EC-like substances 1-AG, DHEA, and PEA were examined by LC-MS/MS in serum samples of nine healthy volunteers employing different pre-analytical sample handling protocols, including prolonged coagulation, and storage after centrifugation at room temperature (RT) or on ice. Furthermore, all analytes were also assessed in plasma samples obtained from the same individuals at the same time points to investigate the comparability between those two blood-based matrices regarding obtained concentrations and their 2-AG/1-AG ratio.
This study shows that ECs and EC-like substances in serum samples were significantly higher than in plasma and are especially prone to ex vivo changes during initial and prolonged storage for coagulation at RT. Storage on ice after centrifugation is less critical. However, storage at RT further increases 1-AG and 2-AG concentrations, while also lowering the already reduced 2-AG/1-AG ratio due to isomerization. Thus, avoidance of prolonged processing at RT can increase data quality if serum as the matrix of choice is unavoidable. However, serum preparation in itself is expected to initiate changes of physiological concentrations as standard precautionary measures like fast and cooled processing can only be utilized by using plasma, which should be the preferred matrix for analyses of ECs and EC-like substances.
Isothermal titration calorimetry (ITC) is a widely used technique for the characterization of protein-protein and protein-ligand interactions. It provides information on the stoichiometry, affinity, and the thermodynamic driving forces of interactions. This chapter exemplifies the use of ITC to investigate interactions between human autophagy modifiers (LC3/GABARAP proteins) and their interaction partners, the LIR motif containing sequences. The purpose of this report is to present a detailed protocol for the production of LC3/GABARAP-interacting LIR peptides using E. coli expression systems. In addition, we outline the design of ITC experiments using the LC3/GABARAP:peptide interactions as an example. Comprehensive troubleshooting notes are provided to facilitate the adaptation of these protocols to different ligand-receptor systems. The methodology outlined for studying protein-ligand interactions will help to avoid common errors and misinterpretations of experimental results.
Simple Summary: The introduction of BRAF/MEK-directed targeted therapy (TT) has significantly improved the management of patients with advanced BRAF-V600-mutant melanoma. Although resistance occurs, there is a subgroup of patients showing a complete response (CR) to TT and who maintain durable disease control. For these patients with durable CR, it is not clear whether it is safe to cease therapy. In this retrospective, multicenter study we have analyzed 37 patients who received TT and achieved a CR upon treatment. We identified 15 patients with a durable CR to TT. Overall, patients who discontinued TT (n = 26) were at higher risk of tumor progression compared to patients receiving ongoing TT. Sustained CR was however not restricted to patients with ongoing TT (n = 11) but was also found in patients who ceased TT (n = 4). Finally, our analysis indicated which patients with an initial CR might be most likely to maintain durable CR upon discontinuation of TT.
Abstract: The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p < 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary real-world cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT.
Tiotropium as an add-on treatment option for severe uncontrolled asthma in preschool patients
(2021)
Background: Toddlers with asthma suffer disproportionally more than school-aged children from exacerbations with emergency visits and hospital admissions despite inhaled corticosteroid (ICS) treatment. A recent trial for children ≤ 5 years showed tolerability of tiotropium and potential to reduce asthma-related events.
Methods: We conducted a retrospective analysis of electronic outpatient records (2017‒2019) of children < 6 years treated with ICS plus long-acting β2-agonists (LABAs) plus tiotropium as an add-on for uncontrolled severe asthma. The primary endpoint was a comparison of systemic corticosteroid (SCS) prescriptions 6 months before and after ICS/LABA/tiotropium start. Secondary endpoints included physician visits, hospitalisations and antibiotic prescriptions. We compared outcomes with children without asthma matched for age, sex, season and screening date.
Results: Compared with a mean 2.42 (95% CI: 1.75, 3.36) SCS courses per patient within 6 months prior to ICS/LABA/tiotropium, 0.74 (95% CI: 0.25, 1.08) SCS courses per patient were prescribed within 6 months after starting ICS/LABA/tiotropium (P< 0.001). Physician visits dropped from 9.23 (95% CI: 7.15, 12.72) to 5.76 (95% CI: 3.10, 7.70) per patient (P< 0.01). Nineteen hospitalisations were recorded 6 months before ICS/LABA/tiotropium compared with one hospitalisation after (P< 0.01). A mean 1.79 antibiotic courses (95% CI: 1.22, 2.23) per patient were prescribed before ICS/LABA/tiotropium compared with 0.74 (95% CI: 0.22, 1.00) after ICS/LABA/tiotropium (P< 0.001). Hospitalisation rates for patients at observation end were not statistically different from healthy controls before/after matching.
Interpretation: Our retrospective study showed that adding tiotropium to ICS/LABA is a new treatment option for patients with severe preschool asthma; however, larger confirmatory studies are needed.
Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1–S126, 2006; or http://www.psoriasis-leitlinie.de).
We have isolated the human protein SNEV as downregulated in replicatively senescent cells. Sequence homology to the yeast splicing factor Prp19 suggested that SNEV might be the orthologue of Prp19 and therefore might also be involved in pre-mRNA splicing. We have used various approaches including gene complementation studies in yeast using a temperature sensitive mutant with a pleiotropic phenotype and SNEV immunodepletion from human HeLa nuclear extracts to determine its function. A human–yeast chimera was indeed capable of restoring the wild-type phenotype of the yeast mutant strain. In addition, immunodepletion of SNEV from human nuclear extracts resulted in a decrease of in vitro pre-mRNA splicing efficiency. Furthermore, as part of our analysis of protein–protein interactions within the CDC5L complex, we found that SNEV interacts with itself. The self-interaction domain was mapped to amino acids 56–74 in the protein's sequence and synthetic peptides derived from this region inhibit in vitro splicing by surprisingly interfering with spliceosome formation and stability. These results indicate that SNEV is the human orthologue of yeast PRP19, functions in splicing and that homo-oligomerization of SNEV in HeLa nuclear extract is essential for spliceosome assembly and that it might also be important for spliceosome stability.
This paper investigates the global stratospheric Brewer–Dobson circulation (BDC) in the ERA5 meteorological reanalysis from the European Centre for Medium-Range Weather Forecasts (ECMWF). The analysis is based on simulations of stratospheric mean age of air, including the full age spectrum, with the Lagrangian transport model CLaMS (Chemical Lagrangian Model of the Stratosphere), driven by reanalysis winds and total diabatic heating rates. ERA5-based results are compared to results based on the preceding ERA-Interim reanalysis. Our results show a significantly slower BDC for ERA5 than for ERA-Interim, manifesting in weaker diabatic heating rates and higher age of air. In the tropical lower stratosphere, heating rates are 30 %–40 % weaker in ERA5, likely correcting a bias in ERA-Interim. At 20 km and in the Northern Hemisphere (NH) stratosphere, ERA5 age values are around the upper margin of the uncertainty range from historical tracer observations, indicating a somewhat slow–biased BDC. The age trend in ERA5 over the 1989–2018 period is negative throughout the stratosphere, as climate models predict in response to global warming. However, the age decrease is not linear but steplike, potentially caused by multi-annual variability or changes in the observations included in the assimilation. During the 2002–2012 period, the ERA5 age shows a similar hemispheric dipole trend pattern as ERA-Interim, with age increasing in the NH and decreasing in the Southern Hemisphere (SH). Shifts in the age spectrum peak and residual circulation transit times indicate that reanalysis differences in age are likely caused by differences in the residual circulation. In particular, the shallow BDC branch accelerates in both reanalyses, whereas the deep branch accelerates in ERA5 and decelerates in ERA-Interim.
The production of Σ0 baryons in the nuclear reaction p (3.5 GeV) + Nb (corresponding to sNN=3.18 GeV) is studied with the detector set-up HADES at GSI, Darmstadt. Σ0s were identified via the decay Σ0→Λγ with subsequent decays Λ→pπ− in coincidence with a e+e− pair from either external (γ→e+e−) or internal (Dalitz decay γ⁎→e+e−) gamma conversions. The differential Σ0 cross section integrated over the detector acceptance, i.e. the rapidity interval 0.5<y<1.1, has been extracted as ΔσΣ0=2.3±(0.2)stat±(−0.6+0.6)sys±(0.2)norm mb, yielding the inclusive production cross section in full phase space σΣ0total=5.8±(0.5)stat±(−1.4+1.4)sys±(0.6)norm±(1.7)extrapol mb by averaging over different extrapolation methods. The Λall/Σ0 ratio within the HADES acceptance is equal to 2.3±(0.2)stat±(−0.6+0.6)sys. The obtained rapidity and momentum distributions are compared to transport model calculations. The Σ0 yield agrees with the statistical model of particle production in nuclear reactions. Keywords: Hyperons, Strangeness, Proton, Nucleus.
Low serum concentrations of the amino acid homoarginine (HA) are associated with increased cardiovascular mortality by incompletely understood mechanisms. This study sought to assess the influence of HA on cardiac remodeling in rats undergoing either transaortic banding or inhibition of nitric oxide synthesis by Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME). Male Wistar rats (n = 136) underwent sham operation (SH) or aortic banding (AB). Both groups were equally divided into 14 subgroups, receiving different doses of HA alone or in combination with lisinopril, spironolactone, or L-NAME for 4 weeks. HA treatment in AB animals resulted in a dose-dependent improvement of cardiac function up to a concentration of 800 mg·kg−1·day−1. Combining 800 mg·kg−1·day−1 HA with spironolactone or lisinopril yielded additional effects, showing a positive correlation with LV ejection fraction (+33%, p = 0.0002) and fractional shortening (+41%, p = 0.0014). An inverse association was observed with collagen area fraction (−41%, p < 0.0001), myocyte cross-sectional area (−22%, p < 0.0001) and the molecular markers atrial natriuretic factor (−74%, p = 0.0091), brain natriuretic peptide (−42%, p = 0.0298), beta-myosin heavy chain (−46%, p = 0.0411), and collagen type V alpha 1 chain (−73%, p = 0.0257) compared to placebo-treated AB animals. Co-administration of HA and L-NAME was found to attenuate cardiac remodeling and prevent NO-deficient hypertension following AB. HA treatment has led to a dose-dependent improvement of myocardial function and marked histological and molecular changes in cardiac remodeling following AB. Combining HA with standard heart failure medication resulted in additional beneficial effects boosting its direct impact on heart failure pathophysiology.